Advertisement

Tumor Biology

, Volume 33, Issue 3, pp 591–600 | Cite as

Pretargeting: taking an alternate route for localizing radionuclides

  • Robert M. Sharkey
  • Chien-Hsing Chang
  • Edmund A. Rossi
  • William J. McBride
  • David M. Goldenberg
Research Article

Abstract

Bispecific antibody pretargeting is a two-step procedure for selectively delivering radionuclides to tumors. The procedure was developed to solve a number of problems encountered when radionuclides are directly coupled to an IgG, such as slow blood clearance and delayed tumor accretion. While various forms of antibody fragments can reduce blood pool activity and provide faster tumor localization, tumor uptake is reduced considerably. In pretargeting procedures, the radionuclide is attached to a small molecule that quickly traverses the vascular barrier to reach the tumor cells, achieving maximum accretion within 0.5 to 1.0 h. Just as quickly, it is eliminated from the body, thereby minimizing tissue exposure and developing high tumor/tissue ratios very early. In order to capture the radionuclide in the tumor, a bispecific antibody (bsMAb) that binds to the tumor and to the isotope carrier (e.g., a hapten-peptide) is pre-administered some time earlier. The pretargeting procedure has been shown repeatedly to improve tumor localization as compared to directly radiolabeled antibodies, thereby enhancing both imaging and therapy. In this article, we review the progress our group has made toward developing and testing bsMAb pretargeting systems for cancer detection and therapy.

Keywords

Bispecific antibody Cancer detection Cancer therapy Pretargeting Radioimmunodetection Radioimmunotherapy 

Notes

Acknowledgments

We thank Dr. Habibe Karacay, Dr. Jacques Barbet, Prof Otto Boerman, Dr. Shankar Vallabhajosula, and Dr. Pat Zanzonico for their assistance in the preclinical studies.

Conflict of interest

C-H Chang, EA Rossi, WJ McBride, and DM Goldenberg are employed or have financial interests in IBC Pharmaceuticals, Inc., and/or Immunomedics, Inc. RM Sharkey has no disclosure.

References

  1. 1.
    Belda-Iniesta C, Ibanez de Caceres I, de Castro J. Monoclonal antibodies for medical oncology: a few critical perspectives. Clin Transl Oncol. 2011;13:84–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov. 2010;9:767–74.PubMedCrossRefGoogle Scholar
  3. 3.
    Reichert JM. Metrics for antibody therapeutics development. mAbs. 2010;2:695–700.PubMedCrossRefGoogle Scholar
  4. 4.
    Sharkey RM, Goldenberg DM. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin. 2006;56:226–43.PubMedCrossRefGoogle Scholar
  5. 5.
    Sharkey RM, Goldenberg DM. Cancer radioimmunotherapy. Immunotherapy. 2011;3:349–70.PubMedCrossRefGoogle Scholar
  6. 6.
    Pouget JP, Navarro-Teulon I, Bardies M, Chouin N, Cartron G, Pelegrin A, Azria D. Clinical radioimmunotherapy-the role of radiobiology. Nat Rev Clin Oncol. 2011;8:720–34.PubMedCrossRefGoogle Scholar
  7. 7.
    Reardan DT, Meares CF, Goodwin DA, McTigue M, David GS, Stone MR, Leung JP, Bartholomew RM, Frincke JM. Antibodies against metal chelates. Nature. 1985;316:265–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Sharkey RM, Motta-Hennessy C, Pawlyk D, Siegel JA, Goldenberg DM. Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts. Cancer Res. 1990;50:2330–6.PubMedGoogle Scholar
  9. 9.
    Colcher D, Pavlinkova G, Beresford G, Booth BJ, Choudhury A, Batra SK. Pharmacokinetics and biodistribution of genetically-engineered antibodies. Q J Nucl Med. 1998;42:225–41.PubMedGoogle Scholar
  10. 10.
    Stickney DR, Anderson LD, Slater JB, Ahlem CN, Kirk GA, Schweighardt SA, Frincke JM. Bifunctional antibody: a binary radiopharmaceutical delivery system for imaging colorectal carcinoma. Cancer Res. 1991;51:6650–5.PubMedGoogle Scholar
  11. 11.
    Stickney DR, Slater JB, Kirk GA, Anderson LD, Chang C-H, Frincke JM. Bifunctional antibody: ZCE/CHA 111Indium BLEDTA-IV clinical imaging in colorectal carcinoma. Antibody Immunoconjug Radiopharm. 1989;2:1–13.Google Scholar
  12. 12.
    Le Doussal JM, Martin M, Gautherot E, Delaage M, Barbet J. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med. 1989;30:1358–66.PubMedGoogle Scholar
  13. 13.
    Gautherot E, Bouhou J, Le Doussal JM, Manetti C, Martin M, Rouvier E, Barbet J. Therapy for colon carcinoma xenografts with bispecific antibody-targeted, iodine-131-labeled bivalent hapten. Cancer. 1997;80:2618–23.PubMedCrossRefGoogle Scholar
  14. 14.
    Gautherot E, Le Doussal JM, Bouhou J, Manetti C, Martin M, Rouvier E, Barbet J. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens. J Nucl Med. 1998;39:1937–43.PubMedGoogle Scholar
  15. 15.
    Gautherot E, Rouvier E, Daniel L, Loucif E, Bouhou J, Manetti C, Martin M, Le Doussal JM, Barbet J. Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten. J Nucl Med. 2000;41:480–7.PubMedGoogle Scholar
  16. 16.
    Hnatowich DJ, Virzi F, Rusckowski M. Investigations of avidin and biotin for imaging applications. J Nucl Med. 1987;28:1294–302.PubMedGoogle Scholar
  17. 17.
    Paganelli G, Magnani P, Fazio F. Pretargeting of carcinomas with the avidin-biotin system. Int J Biol Markers. 1993;8:155–9.PubMedGoogle Scholar
  18. 18.
    Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol. 2006;24:823–34.PubMedCrossRefGoogle Scholar
  19. 19.
    Axworthy DB, Fritzberg AR, Hylarides MD, Mallet RW, Theodore LJ, Gustavson LM, Su F-M, Beaumier PL, Reno JM. Preclinical evaulation of an anti-tumor monoclonal antibody/streptavidin conjugate for pretargeted 90Y radioimmunotherapy in a mouse xenograft model. J Immunother. 1994;16:158.CrossRefGoogle Scholar
  20. 20.
    Axworthy DB, Reno JM, Hylarides MD, Mallett RW, Theodore LJ, Gustavson LM, Su F, Hobson LJ, Beaumier PL, Fritzberg AR. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci U S A. 2000;97:1802–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Kraeber-Bodere F, Faivre-Chauvet A, Ferrer L, Vuillez JP, Brard PY, Rousseau C, Resche I, Devillers A, Laffont S, Bardies M, Chang K, Sharkey RM, Goldenberg DM, Chatal JF, Barbet J. Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen × anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial. Clin Cancer Res. 2003;9:3973S–81.PubMedGoogle Scholar
  22. 22.
    Kraeber-Bodere F, Rousseau C, Bodet-Milin C, Ferrer L, Faivre-Chauvet A, Campion L, Vuillez JP, Devillers A, Chang CH, Goldenberg DM, Chatal JF, Barbet J. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. J Nucl Med. 2006;47:247–55.PubMedGoogle Scholar
  23. 23.
    Chatal JF, Campion L, Kraeber-Bodere F, Bardet S, Vuillez JP, Charbonnel B, Rohmer V, Chang CH, Sharkey RM, Goldenberg DM, Barbet J. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol. 2006;24:1705–11.PubMedCrossRefGoogle Scholar
  24. 24.
    Mirallie E, Vuillez JP, Bardet S, Frampas E, Dupas B, Ferrer L, Faivre-Chauvet A, Murat A, Charbonnel B, Barbet J, Goldenberg DM, Chatal JF, Kraeber-Bodere F. High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer. J Clin Endocrinol Metab. 2005;90:779–88.PubMedCrossRefGoogle Scholar
  25. 25.
    DeNardo SJ, DeNardo GL, Brush J, Carter P. Phage library-derived human anti-TETA and anti-DOTA scFv for pretargeting RIT. Hybridoma. 1999;18:13–21.PubMedCrossRefGoogle Scholar
  26. 26.
    Orcutt KD, Nasr KA, Whitehead DG, Frangioni JV, Wittrup KD. Biodistribution and clearance of small molecule hapten chelates for pretargeted radioimmunotherapy. Mol Imag Biol. 2011;13:215–21.CrossRefGoogle Scholar
  27. 27.
    Morel A, Darmon M, Delaage M. Recognition of imidazole and histamine derivatives by monoclonal antibodies. Mol Immunol. 1990;27:995–1000.PubMedCrossRefGoogle Scholar
  28. 28.
    Morel A, Darmon M, Delaage M. An immunoenzymoassay for histamine. Agents Actions. 1990;30:291–3.PubMedCrossRefGoogle Scholar
  29. 29.
    Janevik-Ivanovska E, Gautherot E, Hillairet de Boisferon M, Cohen M, Milhaud G, Tartar A, Rostene W, Barbet J, Gruaz-Guyon A. Bivalent hapten-bearing peptides designed for iodine-131 pretargeted radioimmunotherapy. Bioconjug Chem. 1997;8:526–33.PubMedCrossRefGoogle Scholar
  30. 30.
    Hosono M, Hosono MN, Kraeber-Bodere F, Devys A, Thedrez P, Faivre-Chauvet A, Gautherot E, Barbet J, Chatal JF. Two-step targeting and dosimetry for small cell lung cancer xenograft with anti-NCAM/antihistamine bispecific antibody and radioiodinated bivalent hapten. J Nucl Med. 1999;40:1216–21.PubMedGoogle Scholar
  31. 31.
    Sharkey RM, McBride WJ, Karacay H, Chang K, Griffiths GL, Hansen HJ, Goldenberg DM. A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res. 2003;63:354–63.PubMedGoogle Scholar
  32. 32.
    McBride WJ, Zanzonico P, Sharkey RM, Noren C, Karacay H, Rossi EA, Losman MJ, Brard PY, Chang CH, Larson SM, Goldenberg DM. Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide. J Nucl Med. 2006;47:1678–88.PubMedGoogle Scholar
  33. 33.
    Griffiths GL, Chang CH, McBride WJ, Rossi EA, Sheerin A, Tejada GR, Karacay H, Sharkey RM, Horak ID, Hansen HJ, Goldenberg DM. Reagents and methods for PET using bispecific antibody pretargeting and 68Ga-radiolabeled bivalent hapten-peptide-chelate conjugates. J Nucl Med. 2004;45:30–9.PubMedGoogle Scholar
  34. 34.
    Karacay H, Sharkey RM, McBride WJ, Rossi EA, Chang CH, Goldenberg DM. Optimization of hapten-peptide labeling for pretargeted immunoPET of bispecific antibody using generator-produced 68Ga. J Nucl Med. 2011;52:555–9.PubMedCrossRefGoogle Scholar
  35. 35.
    McBride WJ, Sharkey RM, Karacay H, D’Souza CA, Rossi EA, Laverman P, Chang CH, Boerman OC, Goldenberg DM. A novel method of 18F radiolabeling for PET. J Nucl Med. 2009;50:991–8.PubMedCrossRefGoogle Scholar
  36. 36.
    McBride WJ, D’Souza CA, Sharkey RM, Karacay H, Rossi EA, Chang CH, Goldenberg DM. Improved 18F labeling of peptides with a fluoride-aluminum-chelate complex. Bioconjug Chem. 2010;21:1331–40.PubMedCrossRefGoogle Scholar
  37. 37.
    D’Souza CA, McBride WJ, Sharkey RM, Todaro LJ, Goldenberg DM. High-yielding aqueous 18F-labeling of peptides via Al18F chelation. Bioconjug Chem. 2011;22:1793–803.PubMedGoogle Scholar
  38. 38.
    Rossi EA, Chang CH, Losman MJ, Sharkey RM, Karacay H, McBride W, Cardillo TM, Hansen HJ, Qu Z, Horak ID, Goldenberg DM. Pretargeting of carcinoembryonic antigen-expressing cancers with a trivalent bispecific fusion protein produced in myeloma cells. Clin Cancer Res. 2005;11:7122s–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Rossi EA, Sharkey RM, McBride W, Karacay H, Zeng L, Hansen HJ, Goldenberg DM, Chang CH. Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy. Clin Cancer Res. 2003;9:3886S–96.PubMedGoogle Scholar
  40. 40.
    Rossi EA, Goldenberg DM, Cardillo TM, McBride WJ, Sharkey RM, Chang CH. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci U S A. 2006;103:6841–6.PubMedCrossRefGoogle Scholar
  41. 41.
    Goldenberg DM, Rossi EA, Sharkey RM, McBride WJ, Chang CH. Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med. 2008;49:158–63.PubMedCrossRefGoogle Scholar
  42. 42.
    Rossi EA, Goldenberg DM, Chang CH: The Dock-and-Lock method combines recombinant engineering with site-specific covalent conjugation to generate multifunctional structures. Bioconjug Chem 2011; doi:  10.1021/bc2004999PMID: 22168444.
  43. 43.
    Karacay H, Sharkey RM, McBride WJ, Griffiths GL, Qu Z, Chang K, Hansen HJ, Goldenberg DM. Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody’s valency for the tumor target antigen. Bioconjug Chem. 2002;13:1054–70.PubMedCrossRefGoogle Scholar
  44. 44.
    Sharkey RM, Cardillo TM, Rossi EA, Chang CH, Karacay H, McBride WJ, Hansen HJ, Horak ID, Goldenberg DM. Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med. 2005;11:1250–5.PubMedCrossRefGoogle Scholar
  45. 45.
    Sharkey RM, Karacay H, Cardillo TM, Chang CH, McBride WJ, Rossi EA, Horak ID, Goldenberg DM. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. Clin Cancer Res. 2005;11:7109s–21.PubMedCrossRefGoogle Scholar
  46. 46.
    Sharkey RM, Karacay H, McBride WJ, Rossi EA, Chang CH, Goldenberg DM. Bispecific antibody pretargeting of radionuclides for immuno single-photon emission computed tomography and immuno positron emission tomography molecular imaging: an update. Clin Cancer Res. 2007;13:5577s–85.PubMedCrossRefGoogle Scholar
  47. 47.
    Sharkey RM, Karacay H, Litwin S, Rossi EA, McBride WJ, Chang CH, Goldenberg DM. Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin’s lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody. Cancer Res. 2008;68:5282–90.PubMedCrossRefGoogle Scholar
  48. 48.
    Sharkey RM, Karacay H, Vallabhajosula S, McBride WJ, Rossi EA, Chang CH, Goldsmith SJ, Goldenberg DM. Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse model. Radiology. 2008;246:497–507.PubMedCrossRefGoogle Scholar
  49. 49.
    Sharkey RM, Karacay H, Johnson CR, Litwin S, Rossi EA, McBride WJ, Chang CH, Goldenberg DM. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma. J Nucl Med. 2009;50:444–53.PubMedCrossRefGoogle Scholar
  50. 50.
    Sharkey RM, Rossi EA, McBride WJ, Chang CH, Goldenberg DM. Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy. Semin Nucl Med. 2010;40:190–203.PubMedCrossRefGoogle Scholar
  51. 51.
    Karacay H, Brard PY, Sharkey RM, Chang CH, Rossi EA, McBride WJ, Ragland DR, Horak ID, Goldenberg DM. Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft. Clin Cancer Res. 2005;11:7879–85.PubMedCrossRefGoogle Scholar
  52. 52.
    Karacay H, Sharkey R, Rossi E, McBride B, Chang C-H, Goldenberg D: A new tri-Fab recombinant bispecific antibody (bsMAb) for pretargeting epithelial cancers: studies with TF12 and 111In-labeled hapten-peptide (IMP 288) in ovarian cancer. J Nucl Med 2010;51:Abst 1148.Google Scholar
  53. 53.
    Karacay H, Sharkey RM, Gold DV, Ragland DR, McBride WJ, Rossi EA, Chang CH, Goldenberg DM. Pretargeted radioimmunotherapy of pancreatic cancer xenografts: TF10-90Y-IMP-288 alone and combined with gemcitabine. J Nucl Med. 2009;50:2008–16.PubMedCrossRefGoogle Scholar
  54. 54.
    Schoffelen R, Sharkey RM, Goldenberg DM, Franssen G, McBride WJ, Rossi EA, Chang CH, Laverman P, Disselhorst JA, Eek A, van der Graaf WT, Oyen WJ, Boerman OC. Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts. Mol Cancer Ther. 2010;9:1019–27.PubMedCrossRefGoogle Scholar
  55. 55.
    Frampas E, Maurel C, Remaud-Le Saec P, Mauxion T, Faivre-Chauvet A, Davodeau F, Goldenberg DM, Bardies M, Barbet J. Pretargeted radioimmunotherapy of colorectal cancer metastases: models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclide. Eur J Nucl Med Mol Imaging. 2011;38:2153–64.PubMedCrossRefGoogle Scholar
  56. 56.
    Bouchet LG, Bolch WE, Blanco HP, Wessels BW, Siegel JA, Rajon DA, Clairand I, Sgouros G. MIRD Pamphlet No 19: absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney. J Nucl Med. 2003;44:1113–47.PubMedGoogle Scholar
  57. 57.
    Siegel JA, Stabin MG, Sharkey RM. Renal dosimetry in peptide radionuclide receptor therapy. Cancer Biother Radiopharm. 2010;25:581–8.PubMedCrossRefGoogle Scholar
  58. 58.
    Wessels BW, Konijnenberg MW, Dale RG, Breitz HB, Cremonesi M, Meredith RF, Green AJ, Bouchet LG, Brill AB, Bolch WE, Sgouros G, Thomas SR. MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response—implications for radionuclide therapy. J Nucl Med. 2008;49:1884–99.PubMedCrossRefGoogle Scholar
  59. 59.
    Schoffelen R, Boerman OC, van der Graff WT, van Herpen CM, Sharkey RM, McBride WJ, Chang CH, Rossi EA, Goldenberg DM, Oyen WJ. Phase I clinical study of the feasibility of pretargeted radioimmunotherapy (PT-RAIT) in patients with colorectal cancer (CRC): first results. J Nucl Med. 2011;52:107 (abstr 358).CrossRefGoogle Scholar
  60. 60.
    Schoffelen R, van der Graaf WT, Franssen G, Sharkey RM, Goldenberg DM, McBride WJ, Rossi EA, Eek A, Oyen WJ, Boerman OC. Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice. J Nucl Med. 2010;51:1780–7.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2012

Authors and Affiliations

  • Robert M. Sharkey
    • 1
  • Chien-Hsing Chang
    • 2
  • Edmund A. Rossi
    • 3
  • William J. McBride
    • 2
  • David M. Goldenberg
    • 1
  1. 1.Garden State Cancer Center at the Center for Molecular Medicine and ImmunologyMorris PlainsUSA
  2. 2.Immunomedics, Inc.Morris PlainsUSA
  3. 3.IBC Pharmaceuticals, Inc. and Immunomedics, Inc.Morris PlainsUSA

Personalised recommendations